Anne Altmeyer - 30 May 2025 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Role
Director
Signature
/s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer
Issuer symbol
CRBP
Transactions as of
30 May 2025
Net transactions value
-$10,096
Form type
4
Filing time
02 Jun 2025, 16:30:13 UTC
Previous filing
03 Jun 2024
Next filing
21 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Altmeyer Anne Director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD /s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer 02 Jun 2025 0001947086

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRBP Common Stock, par value $0.0001 per share Sale $10,096 -1,392 -50% $7.25 1,391 30 May 2025 Direct F1, F2
transaction CRBP Common Stock, par value $0.0001 per share Award $0 +4,800 +345% $0.000000 6,191 30 May 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRBP Stock options (right to buy) Award $0 +16,000 $0.000000 16,000 30 May 2025 Common Stock 16,000 $7.42 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.16 to $7.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
F4 This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.
F5 The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.